An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan
Journal
Hepatology international
Date Issued
2024-01-21
Author(s)
Yu, Ming-Lung
Tai, Chi-Ming
Mo, Lein-Ray
Kuo, Hsing-Tao
Huang, Chung-Feng
Tseng, Kuo-Chih
Lo, Ching-Chu
Bair, Ming-Jong
Wang, Szu-Jen
Huang, Jee-Fu
Yeh, Ming-Lun
Chen, Chun-Ting
Tsai, Ming-Chang
Huang, Chien-Wei
Lee, Pei-Lun
Yang, Tzeng-Hue
Huang, Yi-Hsiang
Chong, Lee-Won
Chen, Chien-Lin
Yang, Chi-Chieh
Hung, Chao-Hung
Yang, Sheng-Shun
Cheng, Pin-Nan
Hsieh, Tsai-Yuan
Hu, Jui-Ting
Wu, Wen-Chih
Cheng, Chien-Yu
Chen, Guei-Ying
Zhou, Guo-Xiong
Tsai, Wei-Lun
Kao, Chien-Neng
Lin, Chih-Lang
Wang, Chia-Chi
Lin, Ta-Ya
Lin, Chih-Lin
Su, Wei-Wen
Lee, Tzong-Hsi
Chang, Te-Sheng
Dai, Chia-Yen
Chen, Chi-Yi
Lin, Han-Chieh
Chuang, Wan-Long
Peng, Cheng-Yuan
Abstract
Both European Association for the Study of the Liver (EASL) and American Association for the Study of Liver Diseases and the Infectious Diseases Society of America (AASLD-IDSA) guidelines recommend simplified hepatitis C virus (HCV) treatment with pan-genotypic sofosbuvir/velpatasvir or glecaprevir/pibrentasvir for eligible patients. This observational study used real-world data to assess these regimens' safety in eligible patients and develop an algorithm to identify patients suitable for simplified treatment by non-specialists.
Subjects
American Association for the Study of Liver Diseases and the Infectious Diseases Society of America; Direct-acting antivirals; European Association for the Study of the Liver; Laboratory abnormalities; Liver function; Safety; Simplified treatment; Taiwan hepatitis C registry; glecaprevir/pibrentasvir; sofosbuvir/velpatasvir
SDGs
Type
journal article